Bashing Accelerated Approval Isn’t Supported by the Data

Principal Tim Franson co-authored an article in STAT, “Bashing accelerated approval isn’t supported by the data,” that discusses the Food and Drug Administration’s (FDA) accelerated approval program.

In the article, Franson notes that many articles have been written stating that certain fast-track drugs, specifically for cancer treatment, have not helped patients live longer or get healthier. He shares “almost all accelerated approval medicines work — but they’re not all necessarily superior to the current standard of care.”

Franson urges the FDA to put data at the forefront of decision making when it comes to fast tracking drugs.

The full article is available to STAT subscribers.